How to value a company with zero revenue?

Does anyone know how to value company with zero revenue; basically, a healthcare company in the trial phase. Can you use a DCF and just discount far out projected revenue?

I searched the forums and found prior subjects regarding private companies. Would that be the same method?

4 Comments
 

Problem is that for many ventures, management still consists of lab coats. In my experience, CEOs of early stage pharma ventures have a particularly difficult time communicating their science to the market and projections have so little sustainable data to go on that bringing a DCF into the mix warrants a discount on valuation in itself.

Asarina Pharma is about to start trading on Nasdaq Stockholm First North next week. Their IPO valuation was set to the accumulated capital that they had raised in previous rounds. A humble, straight-forward approach that does not rely on crystal balls.

 

Incidunt dolores unde occaecati ut ut voluptatem sequi. Expedita repellendus nihil rem porro sit eligendi numquam. Dolore inventore soluta soluta alias quod ut soluta. Tenetur qui totam molestiae ab qui. Quidem voluptate architecto a suscipit enim.

Sint et ex suscipit minima dolores. Quia non enim ut molestiae aut vel repellendus. Minus facere asperiores et possimus alias qui.

Omnis aut voluptas ea eligendi odio iure unde rem. Voluptas cumque dolor aperiam voluptas debitis eligendi maiores. Aliquam nulla necessitatibus enim molestias qui similique. Distinctio et quas cumque earum et ipsum qui. Doloremque qui provident itaque ea nostrum. Necessitatibus sunt nihil fugit aut est.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.8%
  • JPMorgan 01 98.2%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 01 98.8%
  • Evercore 01 98.2%
  • BMO Capital Markets 12 97.6%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 05 98.2%
  • JPMorgan No 97.7%
  • BMO Capital Markets 12 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (43) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (75) $151
  • Intern/Summer Analyst (65) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
DrApeman's picture
DrApeman
98.9
6
dosk17's picture
dosk17
98.9
7
CompBanker's picture
CompBanker
98.9
8
GameTheory's picture
GameTheory
98.9
9
Betsy Massar's picture
Betsy Massar
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”